News
The initiative will provide practical insights into understanding of obesity pathophysiology and its management.
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...
Opinion
GLP-1s, Personalization, and Big Pharma Power Plays: What’s Really at Stake in the Eli Lilly LawsuitThis lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.
NDTV Profit on MSN6d
Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug SectorCipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback